Updated from 9:12 a.m. EDTJohnson & Johnson ( JNJ) said Tuesday that its second-quarter sales rose 4.7% from a year ago, and the health care giant offered optimistic comments about the rest of 2006. The New Brunswick, N.J., company had quarterly sales of $13.4 billion, up from $12.8 billion a year ago. Domestic sales rose 4.4%, and international sales increased 5.1%. J&J earned $2.8 billion and 95 cents a share for the quarter, including a charge of $87 million associated with the acquisition of Vascular Control Systems. Before the charge, the company would have earned 98 cents a share, a penny ahead of estimates. Analysts surveyed by Thomson Financial were also calling for sales of $13.3 billion. Last year's profits totaled $2.6 billion, or 86 cents a share. The second quarter of 2005 had charges of $353 million for the acquisitions of Peninsula Pharmaceuticals, Closure Medical and TransForm Pharmaceuticals and a gain of $225 million for a tax adjustment. "Our second-quarter results demonstrated improving performance which is anticipated to continue throughout the remainder of the year," said William Weldon, J&J's chairman and CEO. "We have made a number of business-building investments and have received several significant regulatory product approvals. These investments and approvals will help us both sustain important leadership positions, as well as enter new high-growth markets characterized by unmet medical need." J&J's shares were recently falling 73 cents, or 1.2%, to $60.18. Sales of medical devices and diagnostics grew 6.2% to $5.2 billion for the second quarter. Pharmaceutical sales advanced 3.2% to $5.8 billion, driven by strong growth from the antipsychotic Risperdal, the inflammatory-disease drug Remicade, the epilepsy and migraine treatment Topamax and the attention-deficit hyperactivity disorder drug Concerta. Detracting from the results were the effects of patent losses on some of J&J's products, including its Duragesic pain-relieving patch.